Clinical Trials Exclude African/Middle Eastern Descent: Understanding the Impact
Wednesday, 11 September 2024, 07:05
The Implications of Exclusion in Clinical Trials
Recent studies indicate that clinical trials are often biased against individuals of African and Middle Eastern descent. This exclusion impacts the efficacy and safety of new cancer treatments. Participants with the 'Duffy-null phenotype', a genetic trait prevalent in these populations, are particularly affected.
Key Findings
- Research indicates a lack of diversity in cancer drug trials.
- Exclusion may result in ineffective treatments for marginalized groups.
- Addressing this issue is critical to public health and health equity.
Call to Action
It is essential for medical researchers and healthcare professionals to prioritize diversity in clinical trials to prevent health disparities.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.